Related Experiment Videos
Modern approach to children with osteogenesis imperfecta
Leonid Zeitlin1, François Fassier, Francis H Glorieux
1Shriners Hospital for Children and McGill University, Montréal, Québec, Canada.
Journal of Pediatric Orthopedics. Part B
|February 14, 2003
Summary
Osteogenesis Imperfecta (OI), a bone fragility disorder, shows promise with bisphosphonate treatment. Pamidronate reduces fractures and pain while improving bone density and mobility.
Area of Science:
- Genetics
- Orthopedics
- Pharmacology
Background:
- Osteogenesis Imperfecta (OI) is a group of genetic disorders characterized by bone fragility.
- Mutations in type I collagen genes are common, but other genetic defects exist in specific OI types.
- Bone fragility in OI results from decreased mass, poor tissue organization, and altered geometry.
Purpose of the Study:
- To evaluate the efficacy of bisphosphonates in managing Osteogenesis Imperfecta.
- To assess the impact of pamidronate on bone resorption, pain, fracture incidence, and bone density.
Main Methods:
- Administration of cyclical intravenous pamidronate.
- Histologic examination of bone tissue.
- Assessment of bone pain, fracture incidence, bone density, and ambulation levels.
Main Results:
- Pamididronate treatment led to reduced bone pain and fracture incidence.
- Significant increases in bone density and ambulation levels were observed.
- Radiographic improvements included increased vertebral body size and cortical bone thickening.
Conclusions:
- Bisphosphonate therapy, specifically pamidronate, is an effective treatment for Osteogenesis Imperfecta.
- This treatment improves bone health and patient mobility, facilitating surgical interventions.
- A multidisciplinary approach, including physiotherapy, is crucial for OI management.